MedTrace Logo

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

NCT00759460 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-09-20

No results posted yet for this study

Summary

The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.

Conditions

Interventions

DRUG

Sertindole

12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days

DRUG

Olanzapine

10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00759460 on ClinicalTrials.gov